Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast CancerW. Fraser Symmans, Smita Asare, Xiuzhen Duan et al.|JAMA Oncology|2021Cited by 110
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapyLili Du, W. Fraser Symmans, Christina Yau et al.|Annals of Oncology|2021Cited by 46
Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trialsMichał Marczyk, Lajos Pusztai, Anna Mrukwa et al.|Annals of Oncology|2022Cited by 22
Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant ChemotherapySunati Sahoo, Idris Tolgay Ocal, Gregor Krings et al.|Archives of Pathology & Laboratory Medicine|2022Cited by 16
Abstract P6-10-02: Assessing biomarkers to inform treatment de-escalation: Mid-treatment biopsy cellularity predicts pCR in the I-SPY 2 TrialSara J. Venters, W. Fraser Symmans, Denise M. Wolf et al.|Cancer Research|2020Cited by 7